ArticleLeukemia2015

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.

K Wenn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.